-Reuters
EyePoint Pharma Highlights Presentation Of Prelim. Data From Phase 1 DAVIO Trial, YUTIQ CALM Registry Study At American Society Of Retina Specialists Meeting
– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD –
– YUTIQ® CALM registry study collecting real-world data on patients with